Impact of poor-quality medicines in the ‘developing’ world

[1]  K. Senior.  Global health-care implications of substandard medicines. , 2008, The Lancet. Infectious diseases.

[2]  C. Mace,et al.  Substandard medicines in resource‐poor settings: a problem that can no longer be ignored , 2008, Tropical medicine & international health : TM & IH.

[3]  A. Attaran,et al.  Antimalarial Drug Quality in the Most Severely Malarious Parts of Africa – A Six Country Study , 2008, PloS one.

[4]  K. Stȩpniewska,et al.  Pharmacokinetic Determinants of the Window of Selection for Antimalarial Drug Resistance , 2008, Antimicrobial Agents and Chemotherapy.

[5]  Christina Y Hampton,et al.  A Collaborative Epidemiological Investigation into the Criminal Fake Artesunate Trade in South East Asia , 2008, PLoS medicine.

[6]  Paul N Newton,et al.  Counterfeit anti-infective drugs. , 2006, The Lancet. Infectious diseases.

[7]  P. Newton,et al.  Manslaughter by Fake Artesunate in Asia—Will Africa Be Next? , 2006, PLoS medicine.

[8]  R. Laing,et al.  Quality and stability of TB medicines: let the buyer beware! , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[9]  O. Shakoor,et al.  Pharmacopoeial quality of drugs supplied by Nigerian pharmacies , 2001, The Lancet.

[10]  M. Reidenberg,et al.  Counterfeit and substandard drugs , 2001, Clinical pharmacology and therapeutics.

[11]  E. Schwartz,et al.  Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria. , 2000, The American journal of tropical medicine and hygiene.

[12]  S. Hill,et al.  Matrix of drug quality reports in USAID-assisted countries by the U.S. Pharmacopeia Drug Quality and Information Program. , 2006 .